grant
New potent orally bioavailable nitro-containing compounds to treat mycobacterial infections
Organization MICHIGAN STATE UNIVERSITYLocation EAST LANSING, UNITED STATESPosted 7 Jul 2025Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025AirAmericanAmikacinAmikinAmiklinAmukinAnti Mycobacterial AgentsAntibiotic AgentsAntibiotic DrugsAntibioticsAntimycobacterial AgentsBacteriaBiclinBiklinBioavailabilityBiogenesisBiological AvailabilityCOPDCell BodyCell FunctionCell PhysiologyCell ProcessCell WallCellsCellular FunctionCellular PhysiologyCellular ProcessCessation of lifeChronicChronic DiseaseChronic IllnessChronic Obstruction Pulmonary DiseaseChronic Obstructive Lung DiseaseChronic Obstructive Pulmonary DiseaseCombination Drug TherapyCystic FibrosisDNA mutationDataDeathDehydrogenasesDevelopmentDiseaseDisorderDrug CombinationsDrug KineticsDrug PrecursorsDrug ToleranceDrug resistanceDrugsElectron TransportEndogenous Nitrate VasodilatorEndothelium-Derived Nitric OxideEnsureEvolutionGenetic ChangeGenetic defectGenetic mutationGenus MycobacteriumHealthHumanIndividualInfectionIntermediary MetabolismLigandsLungLung Respiratory SystemLytotoxicityM abscessusM tbM tuberculosisM tuberculosis infectionM. abscessusM. tbM. tb infectionM. tuberculosisM. tuberculosis infectionM.tb infectionM.tuberculosis infectionMTB infectionMacrophageMammalian CellMedicationMetabolicMetabolic ProcessesMetabolismMiceMice MammalsMicrosomesMiscellaneous AntibioticMissionModern ManMolecular WeightMononitrogen MonoxideMucoviscidosisMulti-Drug ResistanceMultidrug ResistanceMultiple Drug ResistanceMultiple Drug ResistantMurineMusMutationMycobacterial InfectionMycobacteriumMycobacterium InfectionsMycobacterium abscessusMycobacterium tuberculosisMycobacterium tuberculosis (MTB) infectionMycobacterium tuberculosis infectionMycobacteroides abscessusMφNIAIDNTM infectionNational Institute of Allergy and Infectious DiseaseNitric OxideNitrofuransNitrogen MonoxideNitrogen ProtoxideNitroreductasesOralOral AdministrationOral Drug AdministrationOrigin of LifeOxidoreductaseOxidoreductase GeneParentsPatientsPenetrationPharmaceutical PreparationsPharmacokineticsPhysiologic AvailabilityPoisonPolychemotherapyPositionPositioning AttributePro-DrugsProdrugsRecurrenceRecurrentReductasesResistanceResistance to Multi-drugResistance to MultidrugResistance to Multiple DrugResistant to Multiple DrugResistant to multi-drugResistant to multidrugRespirationSeriesSolubilitySpleenSpleen Reticuloendothelial SystemStructure-Activity RelationshipSubcellular ProcessTB infectionTB therapyTB treatmentTherapeuticToxic ChemicalToxic SubstanceTuberculosisUnited Statesanaloganti-microbialantimicrobialantimycobacterialaqueouscell envelopechemical structure functionchronic disorderchronic obstructive pulmonary disordercombination chemotherapycombination pharmacotherapycommunicable disease transmissioncytotoxicitydesigndesigningdevelopmentaldisease transmissiondisseminated TBdisseminated tuberculosisdrug resistantdrug/agentefficacy studyelectron transferendothelial cell derived relaxing factorgenome mutationglobal healthimprovedin vivoinfection due to Mycobacterium tuberculosisinfectious disease transmissioninhibitorintraoral drug deliverymetermouse modelmtbmulti-drug resistantmultidrug resistantmurine modelmutantnon-tuberculosis mycobacterianon-tuberculosis mycobacterialnon-tuberculous mycobacterianon-tuberculous mycobacterialnon-tuberculous mycobacterial infectionnontuberculosis mycobacterialnontuberculous mycobacterianontuberculous mycobacterialnovelparentpre-clinical developmentpreclinical developmentresistance mechanismresistance strainresistance to Drugresistantresistant mechanismresistant strainresistant to Drugrespiratory mechanismside effectstandard of carestructure function relationshiptoxic compoundtreat M. tuberculosistreat Mtbtreat Mycobacterium tuberculosistreat tbtreat tuberculosistuberculosis infectiontuberculosis therapytuberculosis treatmenttuberculous spondyloarthropathy
Description preview
Diseases caused by mycobacteria, including tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) and
non-tuberculous mycobacterial (NTM) infections caused by M. abscessus (Mab), are challenging to treat due to
intrinsic drug tolerance and acquired multi-drug resistance. Mtb requires treatment of up to 6 months, while NTM
requires up to 18…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click